Revista de Gastroenterología del Perú - Volumen 15, Nº3 1995


1. PODOLSKY DK. Inflammatory bowel disease (Review article). N Engl J Med 1991; 325-928-937/1008-1016.

2. STENSON WF., MACDERMO-FT RP. Inflammatory. Bowel Disease IN YAMADA T. ALPERS DH. OWYANG C. POWELL DW. SILVERTEIN FE, (ed): Textbook of Gastroenrology pp 1588-1645. Philadelphia J. B. Lippincott, 1991.

3. MACDERMOTT RP. Alterations in the mucosal immune system in ulcerative colitis and Crohn's disease. Med Clin North Am 78: 1207-12: 31.

4. RAO SSC. READ NW. BROWN C., et at. Studies on the mechanism of bowel disturbance in ulcerative colifis. Gastroenterology. 1993; 93: 34-940.

5. CARPANI DE KASKI M., HODGSON HFJ: Rolling Review inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 567-579.

6. PRESENT DH. Ulcerative colitis. In Bayles TM (ed): Current Therapy in Gastroenterology and Liver Disease pp 387-394, Mosby Year Book Inc. 1994.

7. MINER PB. Left-sided ulcerative colitis and proctitis. In Bayles TM (ed): Current Therapy in Gastroenterology and Liver Disease pp 382-386. Mosby Year Book Inc. 1994.

8. KATZ J The course of inflammatory bowel disease. Med Clin North Am 1994; 78: 1270-1275.

9. PEPPERCORN MA. Inflammatory bowel disease. Medical Therapy. In BARKIN JS, ROGERS Al. (ed). Difficult in Digestive Disease. pp 343-351, Mosby Year Book Inc, 1994.

10. TRUELOVE SC., WITTS LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 2: 1041-1045.

11. LICHTENSTEIN GR: Medical Therapies for inflammatory bowel disease. Cur Opin Gastroenterol 1993; 9: 588-599.

12. WARTS N. Salazopyrin: a new sulfanilamida preparation. Acta Scand 1942; 110: 557-96.

13. GEIER DL., MINER PB. New Therapeutic agents in the Treatment of Inflammatory Bowel Disease. Am J Med 1992; 93: 199-208.

14. PEPPERCORN MA. Advances in Drug Therapy for inflarnatory Bowel Disease. Ann Int Med 1990; 112: 50-60.

15. GREENFIELD SM, PUNCHARD NA, TEARE JP. et al. Review article: The mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 369-383.

16. SUTHERLAND LR., MAY GR., SHAFFER EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118: 540-49.

17. HANAUER SB., BAERT F. Medical Therapy of inflammatory Bowel Disease. Med Clin North Am 78; 1413-1426, 1994.

18. THOMPSON ABR. Review article: New developments in the use of 5-aminoosalicylic acid in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1991; 5: 449-70.

19. BIDDLE WL., GREENBERGER NJ., SWAN JT.. et al. 5Aminosalicilyc acid enemas: efective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988; 94: 1075-79.

20. BOUMPAS DT-, CHROUSOS GP., WILDER RL.. et al. Glucocorticoi steroid. Therapy for immune mediated diseases: Basic and clinical correlates. Ann Inter Med 1993; 119: 1198-1208.

21. LINDMARK B. Short and long term steroid side efects: The importance for patients with inflammatory bowel disease. Res Clin Forums 15: 35-40, 1993.

22. BRATTSAND R. Overview of newer glucocorticosteroid preparation for inflammatory bowel disease. Can J Gastroenterol 1990; 4: 407-414.

23. GREENBERG GR. Newer Steroids: Are we ready to convert?. In LAINE L (ed) AGA Postgraduate Course Evolving Concepts in Gastrointestinal and Liver Disease pp 363-370 San Diego, 1995.

24. EDSBACKER S., WOLLMER P., NILSSON A., et al. Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules. Gastroenterology 1993; 104: A695.

25. LOFBERG R., OSTERGAARD-THOMSEN 0., LANGLOTZ E., et al. Budesonide versus prednisolone enema in active distal ulcerative colitis. A Comparative eight week study. Gut 34 9 suppl: T162-78, 1993.

26. PRESENT DH. 6 Mercaptopurine and other irimmunosuppressive agents in the treatment of Crohn's Disease an Ulcerative colitis. Gastroenterol Clin North Am 18: 57-71. 1989.

27. PRESENT DH., MELTZER SJ., KRUMHOLZ MP., et al. 6 mercaptopurine in the management of inflammatory bowel disease: Short and long-Term toxicity. Ann Inter Med 1989; 111: 641-48.

28. KORELITZ BI. Immunosupressive therapy of inflammatory bowel disease: A Historical Perspective. The Gastroenterologist 1995; 3: 141-154.

29. KOZAREK RA., PATTERSON DJ., GELFAND MD., et al. Long-Term use of methotrexate in inflammatory bowel disease: severe disease 3, drug therapy 2. Seventh inning colitis. Gastroenterology 1992; 102: A648.

30. PRESENT DH. Cyclosporin and other inmmunossuoessive agents: Current and future role in the treatment of inflammatory bowel disease. Am J Gastroenterol 1993; 88: 627-30.

31. LICHTIGER S., PRESENT DH_ KORNBLUTH A., et al. Cyclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-45.

32. CRONSTEIN and WEISSMAN. The adhesion molecules of inflammation. Arthritis and Rheumatism 1993; 36: 147-57.

33. WALLACE JL. STAR WARS: Blocking Cellular Infiltration and Targeting Single Cell populations. In Postgraduate Course Clinical immunology in Gastroenterology and Hepatology: From Bench to Bedside pp 305-309, New Orleans. 1994.

34. PODOLSKY DJ. Attenuation of colitis in the cotton-top tamarin by anti-4 integrin monoclonal antibody. J Clin Invest 1993; 92: 372-80.

35. RAO SSC. . READ NW., DAVIDSON PA.. et al. Anorectal sensivity and responses to rectal distension in patients with ulcerative colitis. Gastroenterology 1987; 93: 1270-75.

36.   HERMENS DJ., MINER PB. Exacerbation of Ulcerative Colitis. Gastroenterology 1991; 101: 254-262.